k 2014

Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients

BEŠŠE, Lenka, Daniela DRANDI, Lenka SEDLAŘÍKOVÁ, Stefania OLIVA, Manuela GAMBELLA et. al.

Basic information

Original name

Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients

Authors

BEŠŠE, Lenka (203 Czech Republic, guarantor, belonging to the institution), Daniela DRANDI (380 Italy), Lenka SEDLAŘÍKOVÁ (203 Czech Republic, belonging to the institution), Stefania OLIVA (380 Italy), Manuela GAMBELLA (380 Italy), Paola OMEDÈ (380 Italy), Zdeněk ADAM (203 Czech Republic), Luděk POUR (203 Czech Republic), Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution), Mario BOCCADORO (380 Italy), Antonio PALUMBO (380 Italy) and Roman HÁJEK (203 Czech Republic, belonging to the institution)

Edition

56th Annual Meeting of the American Society of Hematology, 2014

Other information

Language

English

Type of outcome

Prezentace na konferencích

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/14:00079340

Organization unit

Faculty of Medicine

Keywords in English

Cell-Free DNA; Multiple Myeloma

Tags

Změněno: 3/3/2015 13:36, Ing. Mgr. Věra Pospíšilíková

Abstract

V originále

Circulating nucleic acids, such as cell-free DNA (cf-DNA), are becoming a promising minimally-invasive diagnostic tool for cancer detection. Recent studies demonstrated that tumor-derived cf-DNA can be used to monitor tumor burden and response to treatment in patients (pts) with solid tumors as well as hematological malignancies (Dawson et al, 2013, Armand et al, 2013). In this study we investigated the clinical utility of cf-DNA in the monitoring of minimal residual disease (MRD) of pts with multiple myeloma (MM) carrying the tumor specific immunoglobulin (IGH) rearrangement.